Mad Money's Cramer says investors can always fall back on high-yielding dividend stocks that pay you to wait, like Clorox. Discussing the future of the company, now that it turned down Carl Icahn's $80/share bid, with Donald Knauss, Clorox CEO.
Volatility last week has left some scars, says Jim Iuorio, TJM Institutional Services. "People seem to be ready to tip toe back into the stock market," he says.
Forest Laboratories said it won backing from proxy advisory firm ISS for all 10 of its board nominees in a proxy battle with billionaire investor Carl Icahn.
CNBC's David Faber has the story on whether the billionaire investor is bluffing when he says there's no question he'll be able to raise $7.8 billion to buy the company.
Analysis of billionaire Carl Ichan's bid for the company and whether the stock has room to run, Bill Schmitz, Deutsche Bank Securities, and Javier Escalante, Weeden & Company.
Clorox is "very undervalued," and given the current economic environment "it would be no problem for us to buy it," billionaire investor Carl Icahn told CNBC Friday.
Discussing the internet company's blowout quarter and bright future, with Ken Sena, Evercore Partners, and the Fast Money traders weigh in on Google, Clorox, and natural gas trades to make today.